Why the study?
Adipsin and leptin link adipose tissue dysfunction to obesity-related metabolic disorders, prompting assessment of sitagliptin/metformin versus metformin monotherapy effects on these adipokines and lipid profiles in type 2 diabetic patients.
Does sitagliptin/metformin combination therapy improve adipsin, leptin, and lipid profiles compared to metformin monotherapy in patients with type 2 diabetes?
Does sitagliptin/metformin combination therapy improve adipsin, leptin, and lipid profiles compared to metformin monotherapy in patients with type 2 diabetes?
Sitagliptin/metformin combination therapy may offer superior regulation of adipokines (adipsin, leptin) and lipid profiles compared to metformin alone in type 2 diabetes, potentially providing cardiovascular benefits.
Answers are grounded in this paper and cite their sources.
Sitagliptin/metformin was associated with greater adipokine and lipid improvements than metformin alone; hypothesis-generating for CV effects, needs RCT confirmation before practice change.
Adipsin and Leptin Levels in Type 2 Diabetic Patients on Sitagliptin and Metformin Versus Metformin TherapyT he prevalence of metabolic conditions such as obesity and type 2 diabetes mellitus (T2DM) has risen due to the sedentary lifestyle and excessive calorie consumption that characterize modern living.Obesity and T2DM are among the most urgent global public health issues due to their connection with life-threatening conditions such as heart disease and cancer.[1] Obesity, particularly the atypical development of visceral white adipose tissue (vWAT), enhances the possibility of developing T2DM, which is one of the most common metabolic conditions characterized by a reduction Objectives: Adipsin and leptin are adipokines that link adipose tissue dysfunction and increased fat accumulation to obesityrelated metabolic disorders.This study aimed to assess the effects of sitagliptin/metformin versus metformin monotherapy on the levels of adipsin, leptin, and lipid profile in type 2 diabetic patients.Methods: This comparative case-control study included 120 participants divided into four groups: healthy participants, newly diagnosed type 2 diabetic patients, metformin-treated patients, and sitagliptin/metformin-treated patients.Results: Newly diagnosed type 2 diabetic patients revealed significantly lower adipsin levels, with concomitant higher leptin levels compared to the healthy control group.Adipsin levels were significantly higher and leptin levels were significantly lower in both drug-treated patients compared to newly diagnosed group.Compared to healthy control, there were significantly higher levels of hemoglobin A1c (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and atherogenic index (AI) in the newly diagnosed patients, with significantly lower high-density lipoprotein (HDL) levels.Interestingly, in both treated groups, HbA1c, FBG, TC, TG, VLDL, and AI were significantly decreased compared to newly diagnosed patients.Concomitantly, there are significantly higher levels of HDL in drug-treated group compared to untreated patients.Conclusion: Adipsin is low and leptin is high in diabetic patients which support its possible use as a biomarker for type 2 diabetes.Accordingly, the modification of these adipokines, via the use of drug therapy, has advantageous effects on the cardiovascular system in diabetic patients.Specifically, sitagliptin/metformin regulates adipsin, leptin, and lipid profile to a greater extent than metformin.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: